Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
Go back to Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel| (NASDAQ: ACLX) | Delayed: 115.07 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $115.07 | 52 Week High | $ | |||
| Open | $115.07 | 52 Week Low | $ | |||
| Day High | $115.07 | P/E | N/A | |||
| Day Low | $115.07 | EPS | $ | |||
| Volume | 4 | |||||
| Gilead Sciences (NASDAQ: GILD) | Delayed: 135.82 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $135.82 | 52 Week High | $108.63 | |||
| Open | $135.82 | 52 Week Low | $71.39 | |||
| Day High | $135.82 | P/E | 75.04 | |||
| Day Low | $135.82 | EPS | $1.81 | |||
| Volume | 2,075 | |||||
